Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

1.

The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.

Kenkre VP, Kahl BS.

Curr Hematol Malig Rep. 2012 Sep;7(3):216-20. doi: 10.1007/s11899-012-0127-0. Review.

PMID:
22688757
[PubMed - indexed for MEDLINE]
2.

B-cell receptor pathobiology and targeting in NHL.

Macias-Perez IM, Flinn IW.

Curr Oncol Rep. 2012 Oct;14(5):411-8. doi: 10.1007/s11912-012-0254-8. Review.

PMID:
22865093
[PubMed - indexed for MEDLINE]
3.

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

Burger JA.

Curr Hematol Malig Rep. 2012 Mar;7(1):26-33. doi: 10.1007/s11899-011-0104-z. Review.

PMID:
22105489
[PubMed - indexed for MEDLINE]
4.

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.

Uckun FM, Qazi S.

Expert Rev Anticancer Ther. 2010 Sep;10(9):1407-18. doi: 10.1586/era.10.112. Review.

PMID:
20836676
[PubMed - indexed for MEDLINE]
5.

Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Davids MS, Brown JR.

Leuk Lymphoma. 2012 Dec;53(12):2362-70. doi: 10.3109/10428194.2012.695781. Review.

PMID:
22616724
[PubMed - indexed for MEDLINE]
6.

A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.

Robak P, Robak T.

Curr Med Chem. 2012;19(31):5294-318. Review.

PMID:
22830347
[PubMed - indexed for MEDLINE]
7.

Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.

Burger JA.

Curr Opin Oncol. 2012 Nov;24(6):643-9. doi: 10.1097/CCO.0b013e3283589950. Review.

PMID:
22960555
[PubMed - indexed for MEDLINE]
8.

Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.

Tan SL, Liao C, Lucas MC, Stevenson C, DeMartino JA.

Pharmacol Ther. 2013 May;138(2):294-309. doi: 10.1016/j.pharmthera.2013.02.001. Epub 2013 Feb 7. Review.

PMID:
23396081
[PubMed - indexed for MEDLINE]
9.

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.

Robak T, Robak E.

Expert Opin Investig Drugs. 2012 Jul;21(7):921-47. doi: 10.1517/13543784.2012.685650. Epub 2012 May 22. Review.

PMID:
22612424
[PubMed - indexed for MEDLINE]
10.

Signal transduction inhibitor therapy for lymphoma.

Witzig TE, Gupta M.

Hematology Am Soc Hematol Educ Program. 2010;2010:265-70. doi: 10.1182/asheducation-2010.1.265. Review.

PMID:
21239804
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.

Choi MY, Kipps TJ.

Cancer J. 2012 Sep-Oct;18(5):404-10. Review.

PMID:
23006944
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Targeting pathological B cell receptor signalling in lymphoid malignancies.

Young RM, Staudt LM.

Nat Rev Drug Discov. 2013 Mar;12(3):229-43. doi: 10.1038/nrd3937. Review.

PMID:
23449308
[PubMed - indexed for MEDLINE]
13.

Therapeutic prospect of Syk inhibitors.

Ruzza P, Biondi B, Calderan A.

Expert Opin Ther Pat. 2009 Oct;19(10):1361-76. doi: 10.1517/13543770903207039. Review.

PMID:
19670961
[PubMed - indexed for MEDLINE]
14.

Novel agents in mantle cell lymphoma.

Noel MS, Friedberg JW, Barr PM.

Best Pract Res Clin Haematol. 2012 Jun;25(2):191-200. doi: 10.1016/j.beha.2012.04.001. Epub 2012 Apr 30. Review.

PMID:
22687455
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Novel small molecule therapeutics in rheumatoid arthritis.

Kelly V, Genovese M.

Rheumatology (Oxford). 2013 Jul;52(7):1155-62. doi: 10.1093/rheumatology/kes367. Epub 2013 Jan 7. Review.

PMID:
23297340
[PubMed - indexed for MEDLINE]
16.

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Wiestner A.

Blood. 2012 Dec 6;120(24):4684-91. doi: 10.1182/blood-2012-05-423194. Epub 2012 Aug 8. Review. Erratum in: Blood. 2013 Oct 24;122(17):3090.

PMID:
22875912
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.

Buggy JJ, Elias L.

Int Rev Immunol. 2012 Apr;31(2):119-32. doi: 10.3109/08830185.2012.664797. Review. Erratum in: Int Rev Immunol. 2012 Oct;31(5):428.

PMID:
22449073
[PubMed - indexed for MEDLINE]
18.

Spleen tyrosine kinases: biology, therapeutic targets and drugs.

Riccaboni M, Bianchi I, Petrillo P.

Drug Discov Today. 2010 Jul;15(13-14):517-30. doi: 10.1016/j.drudis.2010.05.001. Epub 2010 May 27. Review.

PMID:
20553955
[PubMed - indexed for MEDLINE]
19.

Inhibitors of the tyrosine kinase signaling cascade for asthma.

Wong WS.

Curr Opin Pharmacol. 2005 Jun;5(3):264-71. Review.

PMID:
15907913
[PubMed - indexed for MEDLINE]
20.

The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.

Haluska F, Pemberton T, Ibrahim N, Kalinsky K.

Semin Oncol. 2007 Dec;34(6):546-54. Review.

PMID:
18083378
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk